Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies

Project: Research

Project Details

StatusActive
Effective start/end date8/10/24 → 8/03/26

Keywords

  • clinical trial
  • Hemophilia B
  • Neutralizing Antibodies
  • Gene Therapy

Clinical Trial Phase

  • Phase III (a & b)